Comparative stages of expression of human squamous carcinoma cells and carcinogen transformed keratinocytes.
The mouse monoclonal antibody OSU 22-3 was prepared using cells from a squamous cell carcinoma (SCC) as an immunogen. This antibody reacts with an antigen found on squamous cell carcinomas but does not react with normal keratinocytes. This antibody and two antibodies that react with normal keratinocytes were used as markers of malignant and normal phenotypes. These markers were used to evaluate several spontaneous and carcinogen initiated SCC tumors and to identify the expression of an antigen associated with a malignant phenotype. A variety of subpopulations in carcinogen initiated tumors and spontaneous SCC tumors were noted. The subpopulations that reacted only with MoAb OSU 22-3 exhibited features of anchorage independent growth and cellular invasiveness, and formed progressively growing tumors in nude mice. Other SCC spontaneous tumor cell subpopulations reacted with the antibodies associated with normal keratinocytes. These cells did not proliferate in vitro and did not form tumors in the nude mouse. There were other carcinogen transformed cells which reacted with MoAb OSU 22-3 but not with the antibodies associated with normal keratinocytes. These cells exhibited anchorage independent growth and cellular invasiveness but did not form tumors in nude mice. We conclude from this work that human SCC tumors contain multiple cell populations. These cell populations have varied growth properties and express surface antigens that may indicate their malignant vigor. Carcinogen transformed keratinocytes do exhibit some of the characteristics of SCC tumor phenotypes but not the property of malignant progressively growing cells on a routine and consistent basis. This feature is transiently and inconsistently expressed in a surrogate host by populations prepared from spontaneous SSC tumors.
Milo
G E
GE
Department of Physiological Chemistry, Ohio State University, Columbus 43210.
Yohn
J
J
Schuller
D
D
Noyes
I
I
Lehman
T
T
D000818:Animals; D000911:Antibodies, Monoclonal; D002273:Carcinogens / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D000078404:Epidermal Cells; D004817:Epidermis / Q000187:drug effects; D006801:Humans; D007633:Keratins; D007928:Lethal Dose 50; D008297:Male; D008769:Methylnitronitrosoguanidine / Q000633:toxicity; D051379:Mice; D008819:Mice, Nude; D009367:Neoplasm Staging; D010641:Phenotype; D012878:Skin Neoplasms / Q000139:chemically induced*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D002273:Carcinogens; D008769:Methylnitronitrosoguanidine; D007633:Keratins